Glenmark Pharmaceuticals Ltd.
GLENMARK
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark's formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.
Shareholding Pattern
| On | Ind. Pro. | Fore. Pro. | FII/FPI | Mutual Funds | Banks | Insurance | Others | Non/Institution |
|---|---|---|---|---|---|---|---|---|
| 2024-09 | 46.65 | 0 | 23.05 | 11.41 | 0 | 0.7 | 1.14 | 17.06 |
| 2024-06 | 46.65 | 0 | 20.98 | 10.92 | 0.08 | 1.95 | 1.01 | 18.41 |
| 2024-03 | 46.64 | 0 | 21.38 | 10.55 | 0.14 | 2.25 | 0.46 | 18.58 |
| 2023-12 | 46.65 | 0 | 23.71 | 8.59 | 0.2 | 1.68 | 0.49 | 18.69 |
| 2023-09 | 46.65 | 0 | 24.79 | 7.3 | 0.2 | 2.44 | 0.42 | 18.21 |
| 2023-06 | 46.65 | 0 | 25.52 | 5.36 | 0.2 | 3.18 | 0.41 | 18.69 |
| 2023-03 | 46.65 | 0 | 22.47 | 5.43 | 0.2 | 4.41 | 0.39 | 20.45 |
| 2022-12 | 46.65 | 0 | 23.19 | 5.64 | 0.2 | 4.48 | 0.42 | 19.42 |
| 2022-09 | 46.65 | 0 | 23.14 | 6.26 | 0.22 | 4.16 | 0.30 | 19.27 |
Results
| On | Income from Inv. | Int. on Bank Bal. | Int. on Advances | Other Int. | Interest Earned | Interest Exp. | Net Interest Income | Expenditure | Operating Income | Other Income | Prov. & Contingencies | PBT | Tax | PAT | Net Profit | Consolidated Net Profit | Adjusted EPS(Rs.) | Gross NPA | Gross NPA(%) | Net NPA | Net NPA(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09 | 0 | 0 | 0 | 0 | 3433.8 | 48.48 | 3385.32 | 2831.88 | 641.33 | 39.42 | 0 | 472.57 | 118.09 | 354.49 | 354.49 | 354.21 | 12.55 | 0 | 0% | 0 | 0% |
| 2024-06 | 0 | 0 | 0 | 0 | 3244.19 | 39.58 | 3204.6 | 2655.97 | 619.71 | 31.49 | 0 | 462.33 | 122.1 | 340.24 | 340.24 | 340.27 | 12.06 | 0 | 0% | 0 | 0% |
| 2024-03 | 0 | 0 | 0 | 0 | 3062.95 | 148.56 | 2914.39 | 2558.61 | 1277.51 | 773.16 | 0 | 530.83 | 1769.47 | -1238.65 | -1214.27 | -1218.28 | -43.17 | 0 | 0% | 0 | 0% |
| 2023-12 | 0 | 0 | 0 | 0 | 2506.7 | 134.34 | 2372.36 | 2715.35 | -163.24 | 45.41 | 0 | -521.38 | -71.8 | -449.58 | -330.81 | -351.37 | -12.45 | 0 | 0% | 0 | 0% |
| 2023-09 | 0 | 0 | 0 | 0 | 3207.38 | 121.46 | 3085.92 | 2745.09 | 463.98 | 1.7 | 0 | -124.35 | 55.95 | -180.3 | -61.56 | -81.95 | -2.90 | 0 | 0% | 0 | 0% |
| 2023-06 | 0 | 0 | 0 | 0 | 3036.07 | 111.61 | 2924.46 | 2598.71 | 457.07 | 19.72 | 0 | 151.4 | 113.72 | 37.68 | 173.13 | 149.93 | 5.31 | 0 | 0% | 0 | 0% |
| 2023-03 | 0 | 0 | 0 | 0 | 3000.51 | 109.14 | 2891.38 | 2602.6 | 355.49 | -42.42 | 0 | -688.4 | -138.9 | -549.49 | -403.14 | -428.3 | -15.18 | 0 | 0% | 0 | 0% |
| 2022-12 | 0 | 0 | 0 | 0 | 3100.18 | 97.11 | 3003.08 | 2626.14 | 544.6 | 70.56 | 0 | 329.86 | 144.09 | 185.77 | 290.76 | 272.58 | 9.66 | 0 | 0% | 0 | 0% |
| 2022-09 | 0 | 0 | 0 | 0 | 3017.93 | 82.94 | 2934.99 | 2538.96 | 565.33 | 86.35 | 0 | 336.62 | 164.83 | 171.79 | 278.67 | 260.44 | 9.23 | 0 | 0% | 0 | 0% |
| 2022-06 | 0 | 0 | 0 | 0 | 2777.29 | 59.99 | 2717.3 | 2345.69 | 614.76 | 183.16 | 0 | 408.01 | 196.91 | 211.11 | 211.11 | 192.53 | 6.82 | 0 | 0% | 0 | 0% |